News headlines about Obalon Therapeutics (NASDAQ:OBLN) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Obalon Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.7379180111508 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern’s analysis:
- Obalon Therapeutics (OBLN) and Uroplasty (UPI) Head to Head Survey (americanbankingnews.com)
- Obalon Therapeutics Announces Proposed Public Offering of Common Stock (finance.yahoo.com)
- Obalon Therapeutics Inc (OBLN) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- $3.88 Million in Sales Expected for Obalon Therapeutics Inc (OBLN) This Quarter (americanbankingnews.com)
- Reviewing Cyberonics (CYBX) & Obalon Therapeutics (OBLN) (americanbankingnews.com)
Shares of Obalon Therapeutics (NASDAQ OBLN) opened at $6.14 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.65 and a current ratio of 8.78. The company has a market capitalization of $119.29, a P/E ratio of -3.09 and a beta of -3.50. Obalon Therapeutics has a one year low of $6.10 and a one year high of $13.18.
OBLN has been the subject of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Obalon Therapeutics in a research report on Thursday, November 16th. Northland Securities reissued a “sell” rating and issued a $4.00 target price on shares of Obalon Therapeutics in a research report on Friday, November 3rd. Zacks Investment Research cut Obalon Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, UBS Group decreased their target price on Obalon Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $12.10.
ILLEGAL ACTIVITY NOTICE: “Obalon Therapeutics (OBLN) Receiving Somewhat Favorable Media Coverage, Accern Reports” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3145733/obalon-therapeutics-obln-receiving-somewhat-favorable-media-coverage-accern-reports.html.
About Obalon Therapeutics
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.